FMF
12
2
3
5
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 12 trials
100.0%
+13.5% vs benchmark
8%
1 trials in Phase 3/4
0%
0 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (12)
Kinesiophobia in Familial Mediterranean Fever
Randomized Controlled Trial in Patients on Long-term Colchicine With Colchicine-resistant Familial Mediterranean Fever (FMF) to Evaluate the Efficacy of On-demand Anakinra Treatment for Painful Attacks in Patients Who Refuse Continuous Daily Therapy
Evaluation of Familial Mediterranean Fever Impact on Oral and Dental Health in Children and Adolescents
Pilates Based Exercises in Patients With Behçet and Familial Mediterranean Fever.
Familial Mediterranean Fever and Behçet: Analysis Before and After Covid19 Pandemic
Safety and Efficacy of RPH-104 Used to Prevent Recurrent Fever Attacks in Adult Patients With Colchicine Resistant or Colchicine Intolerant Familial Mediterranean Fever
Efficacy and Safety of RPH-104 for Resolution and Prevention of Recurring Attacks in Adult Subjects With Familial Mediterranean Fever With Resistance to or Intolerance of Colchicine
FMF and Atheroscelerosis
Phenomics in Autoimmune and Inflammatory Diseases
The Effect of Video Game on Children With Familial Mediterranean Fever
Are Mast Cells Involved in Autoinflammatory Diseases
Colchicine Levels in the Serum of FMF (Familial Mediterranean Fever) Patients